Publication: Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy
Issued Date
2011-01-01
Resource Type
ISSN
09752129
09715851
09715851
Other identifier(s)
2-s2.0-79959454551
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Indian Journal of Medical and Paediatric Oncology. Vol.32, No.1 (2011), 38-42
Suggested Citation
Anant Khositseth, Suwadee Jirasakpisarn, Samart Pakakasama, Lulin Choubtuym, Duangrurdee Wattanasirichaigoon Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy. Indian Journal of Medical and Paediatric Oncology. Vol.32, No.1 (2011), 38-42. doi:10.4103/0971-5851.81889 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/12737
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Carnitine levels and cardiac functions in children with solid malignancies receiving doxorubicin therapy
Other Contributor(s)
Abstract
Aim: Previous studies demonstrated l-carnitine decreasing doxorubicin-induced cardiotoxicity. Our objectives were to study carnitine levels and cardiac functions in children treated with doxorubicin and the effect of short-term l-carnitine supplements. Materials and Methods: Serial carnitine levels and cardiac functions were obtained in children with newly diagnosed solid malignancies before doxorubicin, after cumulative doses of 150 mg/m 2 and 300 mg/m 2 , respectively. Oral l-carnitine 100 mg/kg/day for 3 days were given to the children treated with doxorubicin at cumulative doses of 150 mg/m 2 and 300 mg/m 2 . Carnitine levels and cardiac functions were also obtained in those children before and after short-term oral l-carnitine at each cumulative dose of doxorubicin. Results: Five children (3 females), median age of 9.1 years (range 1.5-13 years) with newly diagnosed solid malignancies were enrolled in the study. Free carnitine (FC) tended to decrease while acyl-carnitine (AC) increased making AC/FC ratio increased after cumulative dose of 150 and 300 mg/m 2 but the statistics was not significant. Left ventricular (LV) systolic function was not significantly changed. Interestingly, LV global function (LV myocardial performance index) was significantly increased after 150 mg/m 2 (median 0.39, 0.27-0.51) and 300 mg/m 2 (median 0.46, 0.27-0.50) when compared to baseline (median 0.28, 0.14-0.48) (P=0.05). Carnitine levels and cardiac functions were not significantly changed after oral l-carnitine supplement at cumulative dose of 150 mg/m 2 (n=6) and 300 mg/m 2 (n=9). Conclusions: Carnitine levels tended to decrease after doxorubicin treatment. LV global dysfunction was documented early after doxorubicin. However, short-term l-carnitine supplement did not improve cardiac function.